Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review
Pancreatic adenocarcinoma (PDAC) is disease with a 5-year survival of only 12%. Many patients with PDAC present with late-stage disease and even early-stage disease can often be characterized by an aggressive tumor biology. Standard therapy for metastatic PDAC consists mainly of chemotherapy regimen...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2024-03-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/29/3/10.31083/j.fbl2903101 |
| _version_ | 1797238594543288320 |
|---|---|
| author | Samantha M. Ruff Timothy M. Pawlik |
| author_facet | Samantha M. Ruff Timothy M. Pawlik |
| author_sort | Samantha M. Ruff |
| collection | DOAJ |
| description | Pancreatic adenocarcinoma (PDAC) is disease with a 5-year survival of only 12%. Many patients with PDAC present with late-stage disease and even early-stage disease can often be characterized by an aggressive tumor biology. Standard therapy for metastatic PDAC consists mainly of chemotherapy regimens like FOLFIRINOX, FOLFOX, or gemcitabine and nab-paclitaxel. Research has focused on sequencing PDAC tumors to understand better the mutational landscape and transcriptomics of PDAC with the goal to develop targeted therapies. Targeted therapies may potentially minimize the toxic risks of chemotherapy and provide a long-term survival benefit. We herein review the underlying molecular pathogenesis of PDAC, as well as the classification schema created from current sequencing data, and recent updates related to targeted therapy for PDAC. |
| first_indexed | 2024-04-24T17:38:08Z |
| format | Article |
| id | doaj.art-0cd93548a1224e1abe6b2f6aa9ef6805 |
| institution | Directory Open Access Journal |
| issn | 2768-6701 |
| language | English |
| last_indexed | 2024-04-24T17:38:08Z |
| publishDate | 2024-03-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj.art-0cd93548a1224e1abe6b2f6aa9ef68052024-03-28T02:27:54ZengIMR PressFrontiers in Bioscience-Landmark2768-67012024-03-0129310110.31083/j.fbl2903101S2768-6701(24)01224-3Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A ReviewSamantha M. Ruff0Timothy M. Pawlik1Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USADepartment of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USAPancreatic adenocarcinoma (PDAC) is disease with a 5-year survival of only 12%. Many patients with PDAC present with late-stage disease and even early-stage disease can often be characterized by an aggressive tumor biology. Standard therapy for metastatic PDAC consists mainly of chemotherapy regimens like FOLFIRINOX, FOLFOX, or gemcitabine and nab-paclitaxel. Research has focused on sequencing PDAC tumors to understand better the mutational landscape and transcriptomics of PDAC with the goal to develop targeted therapies. Targeted therapies may potentially minimize the toxic risks of chemotherapy and provide a long-term survival benefit. We herein review the underlying molecular pathogenesis of PDAC, as well as the classification schema created from current sequencing data, and recent updates related to targeted therapy for PDAC.https://www.imrpress.com/journal/FBL/29/3/10.31083/j.fbl2903101pancreatic cancertargeted therapymolecular subtypesnext generation sequencing |
| spellingShingle | Samantha M. Ruff Timothy M. Pawlik Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review Frontiers in Bioscience-Landmark pancreatic cancer targeted therapy molecular subtypes next generation sequencing |
| title | Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review |
| title_full | Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review |
| title_fullStr | Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review |
| title_full_unstemmed | Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review |
| title_short | Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review |
| title_sort | molecular classification and pathogenesis of pancreatic adenocarcinoma and targeted therapies a review |
| topic | pancreatic cancer targeted therapy molecular subtypes next generation sequencing |
| url | https://www.imrpress.com/journal/FBL/29/3/10.31083/j.fbl2903101 |
| work_keys_str_mv | AT samanthamruff molecularclassificationandpathogenesisofpancreaticadenocarcinomaandtargetedtherapiesareview AT timothympawlik molecularclassificationandpathogenesisofpancreaticadenocarcinomaandtargetedtherapiesareview |